Drugs that contain Bedaquiline Fumarate

1. List of Sirturo drug patents

SIRTURO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7498343 JANSSEN THERAP Mycobacterial inhibitors
Dec, 2026

(3 years from now)

US8546428 JANSSEN THERAP Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
Mar, 2029

(5 years from now)

Do you want to check out SIRTURO patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 9, 2026

Market Authorisation Date: 28 December, 2012

Treatment: Treatment of pulmonary multi-drug resistant tuberculosis

Dosage: TABLET;ORAL

More Information on Dosage

SIRTURO family patents

6

European Union

4

China

3

Israel

3

Croatia

3

Denmark

3

Spain

3

Cyprus

3

Portugal

3

Japan

3

Norway

3

Hong Kong

3

Slovenia

3

United States

AP

2

AP

2

Australia

EA

2

EA

2

Korea, Republic of

2

Canada

2

New Zealand

2

Malaysia

2

ME

2

Ukraine

2

Poland

2

Mexico

2

Argentina

2

South Africa

2

Brazil

2

Taiwan

1

Iceland

1

Luxembourg

1

Netherlands

YU

1

Yugoslavia

1

Uruguay

1

Peru

1

Austria

1

Chile

1

Jordan

1

Germany

1

RS

1

Hungary

1

Belgium

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in